Portal de investigación
Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Solsona M
- Berrueco R
- Sebastián E
- Cervera Á
- Sastre A
- Astigarraga I
- Dasí MÁ
- Dapena JL
Grupos
Abstract
It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar-TPO) withdrawal in paediatric patients. A multicentre retrospective observational study was performed in children with chronic immune thrombopenia (cITP) to describe ar-TPO tapering and withdrawal in patients who had achieved a sustained complete response to ar-TPOs. Ten patients (eltrombopag n = 6, romiplostim n = 4) were included. Treatment withdrawal was performed after a mean tapering time of 7.6 months. Two patients relapsed (median follow-up time of 24 months). Slow tapering and withdrawal of ar-TPOs can be safely performed in cITP paediatric patients after achieving a sustained complete response.
© 2022 British Pharmacological Society.
Datos de la publicación
- ISSN/ISSNe:
- 0306-5251, 1365-2125
- Tipo:
- Article
- Páginas:
- 4220-4223
- DOI:
- 10.1111/bcp.15378
- PubMed:
- 35491467
- Factor de Impacto:
- 1,055 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY WILEY
Documentos
- No hay documentos
Filiaciones
Keywords
- drug utilization; paediatrics; platelets
Campos de Estudio
Cita
Solsona M,Berrueco R,Sebastián E,Cervera Á,Sastre A,Astigarraga I,ARGILÉS B,Dasí MÁ,Dapena JL,MONTEAGUDO E. Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?. Br. J. Clin. Pharmacol. 2022. 88. (9):p. 4220-4223. IF:3,400. (2).